Novo Nordisk and Eli Lilly (NYSE:LLY) shares edged higher Tuesday following results from Viking Therapeutics’ Phase 2 VENTURE-Oral Dosing trial for its oral obesity treatment.

The UK list price of the weight loss drug could nearly triple, but which patients will bear the brunt of the internationally “aligned” cost? Kate Bowie reports In May the Trump administration demanded ...

Viking Therapeutics shares plunged 40% after trial data for its obesity pill, VK2735, revealed high dropout rates due to side ...

Viking Therapeutics' stock crashed 40% in early trading on Tuesday after a phase 2 trial of its weight-loss pill showed a ...

Today’s announcement (August 20) on draft guidelines from the UK’s National Institute for Health and Care Excellence (NICE) ...

A Shropshire GP has said many patients are worried about having to stop their weight loss journey as the cost of Mounjaro is ...

Ozempic accidentally became a cultural phenomenon. The drug, first delivered to diabetes patients in 2017, had a huge impact ...

With the price of Mounjaro set to rise, many are hoping for a replacement and a new drug could be out next year ...

It comes after Mounjaro's manufacturer, Eli Lilly, announced it would be increasing the price of the GLP-1 jabs in the UK by ...

Trump calls for API stockpile, OCOchem to scale up chemicals from carbon dioxide, Covestro to buy isocyanates plants, and ...

The Summit is the Premier Industry Event for Defining How New Product Planning Teams and Related Functions Make Informed, Value-Based, Data-Driven Decisions ~ ~ Ensysce Biopharma Leader to Deliver ...

Mass General Brigham researchers identified seven molecules in the blood linked to excessive daytime sleepiness, including factors related to diet and ...